Artios exploits a DDR‑based platform and small‑molecule drug discovery capabilities to build a pipeline of next‑generation cancer therapies. Its pipeline includes ATR inhibitor ART0380, which is in a Phase 1 clinical study, and a potential first‑in‑class DNA polymerase theta (Polθ) inhibitor ART4215 planned for first‑in‑human studies in the second half of 2021. The company collaborates with Cancer Research UK and research groups including The Institute of Cancer Research, the Netherlands Cancer Institute and the Crick Institute. Artios has partner agreements with Merck KGaA (opt‑in on up to eight targets with milestone potential of up to $860M per target) and a collaboration with Novartis that included a $20M up‑front payment and up to $1.3B in milestones plus royalties. Artios is based at the Babraham Research Campus in Cambridge, UK, and has an office in New York City. The company has strengthened its balance sheet through equity financings, including a $153M Series C, bringing total capital raised to more than $320M to date. Artios is a Cambridge-based biotech focused on developing cancer therapeutics. The company was the subject of an $84 million development round reported in the article. That financing attracted participation from large pharmaceutical companies Pfizer and Novartis. The round is described as a development-stage financing intended to advance the company’s oncology drug programs. The deal underscores continued investor interest in cancer drug development. No operating metrics or additional financial terms were disclosed in the article.

Total raised

$236M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2021